Key facts
- A phase 3 trial tested adding the immunotherapy pembrolizumab to stereotactic body radiotherapy (SBRT) for early-stage non-small cell lung cancer.
- The combination did not improve event-free survival, and the trial was stopped early.
- The idea came from a promising phase 2 result — a reminder that early signals often do not hold up.
What happened
A phase 3 trial combining the immune checkpoint inhibitor pembrolizumab with stereotactic body radiotherapy (SBRT) in early-stage non-small cell lung cancer (NSCLC) failed to improve event-free survival compared with SBRT alone, and was halted early. The combination had been built on an encouraging phase 2 signal, which did not translate into benefit in the larger, definitive study.
Why it matters
SBRT — highly focused, high-dose radiotherapy given in a few sessions — is a standard option for people with small lung cancers who cannot have surgery or prefer not to, often because of age, heart disease or chronic lung disease. Some of these cancers come back later, so researchers hoped that adding immunotherapy, which is already effective in more advanced lung cancer, would lower the risk of recurrence.
The negative result means SBRT alone remains the standard for this group outside clinical trials. It also spares patients the cost and potential side effects of immunotherapy, such as inflammation of the lungs, bowel or thyroid, when it does not help.
Background: why phase 2 results can mislead
Phase 2 trials are smaller, often have fewer events and may compare against historical data rather than a randomised control group. Promising differences in these settings frequently shrink or disappear in phase 3. That is why treatment guidelines rely on large randomised trials before changing practice.
What it means for clinicians and students
- Clinicians: continue to offer SBRT alone for medically inoperable early NSCLC, and consider clinical trials for patients interested in new approaches.
- Patients: if you are having SBRT, ask your oncologist about follow-up imaging and how recurrences are detected and treated.
- Dental and surgical teams: many of these patients are older and have heart and lung disease — plan procedures with this in mind.
- Students: a textbook example of why phase 2 signals need confirmation in phase 3 trials.
Source: Medscape Medical News















